西妥昔单抗联化疗.pptVIP

Treatment with XP+C was well-tolerated and effective as first line therapy in AGC Severity of skin rash is strongly related with treatment efficacy. EGF A61G polymorphism is related with treatment efficacy. EGFR gene copy numbers, TGFα may help to predict clinical outcome, especially co-detection of some biomarkers such as TGFα and EGF polymorphism. Conclusion 致 谢 默克雪兰诺公司 其余六家临床中心： 解放军307医院 中国医学科学院肿瘤医院 青岛大学附属医院 浙江大学第一附属医院 黑龙江省肿瘤医院 上海长征医院 解放军307医院肿瘤中心 刘慧龙博士 For more information and communication E-mail: zhangxtxx@ Tel： * * * Eligibility criteria for the ToGA trial include: 18 years of age, HER2-positive histologically confirmed gastric cancer or gastro-oesophageal adenocarcinoma, with inoperable, locally advanced or recurrent and/or metastatic disease. The ToGA trial planned to recruit 584 patients. An additional 10 patients, who had already signed the informed consent form when the screening cut-off was reached, were allowed to enter the trial, resulting in a total of 594 patients recruited. The primary end point is overall survival in the two treatment arms. Secondary end points include progression-free survival, overall response rate, clinical benefit rate, duration of response and safety profile. * * * 西妥昔单抗联合化疗——胃癌一线治疗的新契机chances of cetuximab in the first line treatment of AGC 张 小 田 北京大学临床肿瘤学院消化内科 Dr. Xiaotian Zhang GI Department, Peking University, School of Oncology (PUSC) Can target therapy break the bottleneck of chemotherapy in gastric cancer? Current status of AGC chemotherapy ORR: 40~50% Overall survival less than 1 year Poor Tolerance 西妥昔单抗可否成为晚期胃癌治疗的新契机？ 契机 哲学：德文moment的意译 英文：Chance， moment ，turning point 中文：通常指事物发展过程中的关键、枢纽或决定 性的环节 Cetuximab Panitumumab Trastuzumab Gefitnib Erlotinib Imatinib TKR ISIS 2503 FT1 bevacizumab VatalanibSU5416 p53 PLC P13K G3139 Bcl-2 Caspase p70S6K PKC Raf Mek Akt Rac PKC Ca2＋ IP3 DAG ERK/MAPK 血管通透性改变 转录/增殖 P27 P21 细胞凋亡 sorafenib EGF VEGF AKT Ras P53 P13K PLC VEGFR VEG